Academic literature on the topic 'Hematology'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hematology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hematology"

1

Clark, Sherrie G., and Natalie Coffer. "Normal Hematology and Hematologic Disorders in Potbellied Pigs." Veterinary Clinics of North America: Exotic Animal Practice 11, no. 3 (September 2008): 569–82. http://dx.doi.org/10.1016/j.cvex.2008.03.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

May, Jori E., Patrick C. Irelan, Kailee Boedeker, Emily Cahill, Steven Fein, David A. Garcia, Lisa K. Hicks, et al. "Systems-based hematology: highlighting successes and next steps." Blood Advances 4, no. 18 (September 22, 2020): 4574–83. http://dx.doi.org/10.1182/bloodadvances.2020002947.

Full text
Abstract:
Abstract Systems-based hematology is dedicated to improving care delivery for patients with blood disorders. First defined by the American Society of Hematology in 2015, the idea of a systems-based hematologist arose from evolving pressures in the health care system and increasing recognition of opportunities to optimize the quality and cost effectiveness of hematologic care. In this review, we begin with a proposed framework to formalize the discussion of the range of initiatives within systems-based hematology. Classification by 2 criteria, project scope and method of intervention, facilitates comparison between initiatives and supports dialogue for future efforts. Next, we present published examples of successful systems-based initiatives in the field of hematology, including efforts to improve stewardship in the diagnosis and management of complex hematologic disorders (eg, heparin-induced thrombocytopenia and thrombophilias), the development of programs to promote appropriate use of hematologic therapies (eg, blood products, inferior vena cava filters, and anticoagulation), changes in care delivery infrastructure to improve access to hematologic expertise (eg, electronic consultation and disorder-specific care pathways), and others. The range of projects illustrates the broad potential for interventions and highlights different metrics used to quantify improvements in care delivery. We conclude with a discussion about future directions for the field of systems-based hematology, including extension to malignant disorders and the need to define, expand, and support career pathways.
APA, Harvard, Vancouver, ISO, and other styles
3

Tahmasebi, Houman, Victoria Higgins, Mary Kathryn Bohn, Alexandra Hall, and Khosrow Adeli. "CALIPER Hematology Reference Standards (I)." American Journal of Clinical Pathology 154, no. 3 (June 20, 2020): 330–41. http://dx.doi.org/10.1093/ajcp/aqaa059.

Full text
Abstract:
Abstract Objectives Accurate hematologic test interpretation based on normative reference standards is critical to ensure appropriate clinical decision making. However, healthy pediatric reference data for most hematology parameters are lacking. To address this gap, this study establishes age- and sex-specific hematologic reference standards in the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) cohort of healthy children and adolescents. Methods Fresh whole blood samples collected from a total of 566 healthy children and adolescents (birth to <21 years) with informed consent were analyzed for 47 hematologic parameters on the Beckman Coulter DxH 900. Age- and sex-specific reference standards were calculated based on the Clinical and Laboratory Standards Institute guidelines. Results Reference value distributions for most hematology parameters demonstrated dynamic changes across the pediatric age range with significant age-specific differences observed for 39 of the 47 parameters examined. Sex-specific differences were also observed for eight hematologic parameters, primarily during and after puberty. Conclusions This study establishes a robust database of pediatric reference standards for 47 hematologic parameters in the CALIPER cohort for the first time. These comprehensive reference value data sets report potentially important and physiologically relevant trends in hematologic markers, clearly demonstrating the need for pediatric reference standards for hematologic test interpretation.
APA, Harvard, Vancouver, ISO, and other styles
4

Prabhat, Daksha, Tejaswini Waghmare, and Tasneem Rangwala. "Utility of Hematology Histograms." Annals of Pathology and Laboratory Medicine 6, no. 5 (May 24, 2019): A309–319. http://dx.doi.org/10.21276/apalm.2527.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Francis, J. L. "Hematology." Blood Coagulation & Fibrinolysis 2, no. 4 (August 1991): 575. http://dx.doi.org/10.1097/00001721-199108000-00011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Hematology." American Journal of Clinical Oncology 16, no. 2 (April 1993): 184. http://dx.doi.org/10.1097/00000421-199304000-00027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Beirne, O. Ross. "Hematology." Journal of Oral and Maxillofacial Surgery 66, no. 8 (August 2008): 3. http://dx.doi.org/10.1016/j.joms.2008.05.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

MESSICK, J. "Hematology." Veterinary Clinics of North America: Small Animal Practice 33, no. 6 (November 2003): xiii. http://dx.doi.org/10.1016/s0195-5616(03)00124-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Manspeizer, Heather E. "Hematology." Journal of Cardiothoracic and Vascular Anesthesia 15, no. 2 (April 2001): 269. http://dx.doi.org/10.1016/s1053-0770(01)70009-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Messick, Joanne B. "Hematology." Veterinary Clinics of North America: Small Animal Practice 42, no. 1 (January 2012): xi—xii. http://dx.doi.org/10.1016/j.cvsm.2011.11.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Hematology"

1

Linnér, Jonathan. "Flödescytometri : Metodverifiering av flödescytometri med immunologisk tillämpning." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-64927.

Full text
Abstract:
Introduktion: Lymfocyter är celler som ingår i immunförsvar mot patogener och kan delas in i T- och B-lymfocyter. Lymfom är solida neoplasier som framför allt kan drabba lymfocyterna och olika lymfom uttrycker olika immunofenotyper. Flödescytometri är en mycket effektiv teknik för att särskilja olika lymfom. Tekniken kan differentiera celler i en vätskeström genom att dessa bestrålas med monokromatiskt ljus av olika våglängder. Ljusbrytningen framåt och 90° åt sidan ger information om cellernas storlek respektive innehåll, medan fluorokromkonjugerade antikroppar identifierar immunofenotyperna på cellerna. Fluorokromer exciterar ljus av en viss våglängd och emitterar ljus av en längre våglängd. Studien syftade till att applicera flödescytometern FACSCanto II:s tredje laser, så att fler fluorokromer ska kunna användas vid antikroppsbaserad lymfomdiagnostik. Material och metod: Provmaterialet var lymfkörtlar och benmärg. Åtta patientfall med lymfomfrågeställning i anamnesen, samt ett normalblod som kontroll, analyserades med LST:s antikroppsreagens parallellt med befintlig antikroppsreagens. De instrument-inställningar som behövdes gjordes under två dagar under handledning av en applikationsspecialist från företaget BD Biosciences. Resultat: De nya fluorokromerna separerade lymfocytpopulationerna bra i diagrammen. Det kunde inte påvisas någon signifikant skillnad mellan LST- och den befintliga antikroppsreagensen. Diskussion och slutsats: Antalet prover kan ha varit lite för lågt för de statistiska slutsatser som dragits. Resultatet verkar ändå lovande för klinisk applicering av den tidigare oanvända lasern hos FACSCanto II. LST-rörets antikroppsreagens saknade några viktiga CD-markörer samt innehöll CD-markörer som upplevdes som överflödiga. LST-rörets fördelar mot nackdelar kommer ändå att övervägas vidare och kan bli aktuell på klinisk patologi i Kalmar.
APA, Harvard, Vancouver, ISO, and other styles
2

Magnin, Olivier. "Diffractive optics applied to hematology." Université Louis Pasteur (Strasbourg) (1971-2008), 2002. https://publication-theses.unistra.fr/public/theses_doctorat/2002/MAGNIN_Olivier_2002.pdf.

Full text
Abstract:
Ce travail de thèse porte sur la caractérisation des cellules sanguines par méthodes optiques. Nous proposons de concevoir et fabriquer un élément optique diffractif particulièrement adapté à la différenciation des cellules sanguines et de l'intégrer dans un système approprié. Ce composant est étudié afin de prendre en compte les contraintes propres à la cytometrie en flux et à la synthèse d'éléments diffractifs. Nous montrons que ce composant permet d'améliorer les perfomances pour un coût de fabrication inférieur aux systèmes actuels. Compte tenu de la spécificité du domaine de l'hématologie, nous procédons d'abord à une rapide présentation des bases de l'hématologie et de la cytométrie en flux. Nous traiterons ensuite du cahier des charges, de la synthèse et de la réalisation de l'élément diffractif puis de son intégration suivie d'une validation expérimentale. Nous prenons en charge toutes les étapes: spécifications, calcul de la fonction de phase, simulation des performances et synthèse des fichiers de fabrication. Une fois le prototype réalisé, l'élément diffractif, après avoir été testé isolément, est intégré dans le système optique de caractérisation de cellules sanguines. Nous discutons ensuite cette intégration. Des tests permettent de mettre en évidence le gain de précision et de fiabilité apporté par le système réalisé. Nous concluons en faisant un bilan des résultats et en présentant des éléments de prospectives
The topic of this thesis is blood cells characterization by optical methods. Throughout this work we propose to design and realize a diffractive beam shaper especially adapted to blood cells differentiation, the beam shaper will be next integrated in a blood cell analyzer. The proposed diffractive beam shaper is globally optimized taking into account specific constraints of flow cytometry optical measurements as well as constraints linked to diffractive optics design and fabrication. The proposed design will reduce misalignments sensitivity and enhance measurement accuracy at lower cost than standard optical setups. In order to set the context of the study we first introduce the required hematology and flow cytometry backgrounds. The rest of the work focuses on the proposed diffractive beam shaper synthesis: specifications, phase function determination, prototype fabrication and experimental validation. Prototypes of the proposed diffractive beam shaper have been realized. Those prototypes have first been tested and validated as stand alone optical components. They have next been integrated in the overall optical blood cells differentiation system. Experiments we have realized have proven that the proposed diffractive beam shaping function is especially adapted to optical blood cells characterization: alignment and tolerancing of one critical component have been relaxed and measurement stability has been enhanced
APA, Harvard, Vancouver, ISO, and other styles
3

ORRU', FEDERICA. "Role of Telomeres in Onco-Hematology." Doctoral thesis, Università degli Studi di Cagliari, 2017. http://hdl.handle.net/11584/249705.

Full text
Abstract:
Telomeres are protective structure located on the endings of human chromosomes, that prevent translocation and progressive shortening of DNA coding sequences. Several studies showed that telomeres are involved in regulation of cell lifespan and proliferative potential. The role of telomeres in oncogenesis is still a matter of active investigation. Recently, some papers identified telomere length alterations in patients affected by Chronic Myeloid Leukemia and Myelofibrosis. My research activity focused on the relation between telomere length and the outcome of patients with Chronic Myeloid Leukemia and Myelofibrosis. My aim was to investigate new therapeutic targets and outcome predictive factors. In particular, I pursued two research lines: first, I tried to evaluate the role of telomeres as biomarker to discriminate patients with Chronic Myeloid Leukemia that could safely stop tyrosine kinase therapy. Next, I investigated the relation between telomere length and response to Ruxolitinib, a recently approved JAK-STAT inhibitor, who proved to be highly beneficial to high-risk patients with Myelofibrosis. I enrolled a population of 32 patients affected by Chronic Myeloid Leukemia who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls, for whom was possible to evaluate telomere length. I performed the clinical management of these patients and the data analysis. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL) was also obtained. The 36-month probability of treatment-free remission (TFR) was 59.4 %. TFR patients showed shorter acRTL compared to relapsed (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; p = 0.01). TFR was significantly higher in CML patients with acRTL ≤0.09 (78.9 vs 30.8 %, p = 0.002). These findings indicate that telomere length seems to be related to treatment free remission in CML patients, and may be a useful biomarker to select patients candidate to treatment interruption. Next, I enrolled a population of 11 patients affected by Myelofibrosis, eligible to Ruxolitinib treatment, for whom was possible to evaluate telomere length before and after a median of 1000 days of Ruxolitinib therapy. I performed the clinical management of this cohort, and the data analysis. The RTL was determined as stated before. Related samples Wilcoxon signed-rank test performed before treatment with Ruxolitinib showed that the mean RTL was shorter in patients compared with age-and sex-matched healthy controls (1.08 vs 1.26, respectively; P = 0.09). The most interesting finding was that Mann-Whitney Utest showed shorter acRTL in MF patients with high IPSS compared to patients with intermediate-2 IPSS (mean ± SD = 1.016 ± 0.22 vs 1.34 ± 0.14; p= 0.03); furthermore, median RTL increased significantly (1.30 vs 1.08; p = 0.018), showing overlapping values with the healthy controls. Median RTL elongation from baseline was 15%. These findings seem to indicate that telomeres are involved in the dynamics of Myelofibrosis evolution and treatment response, and may be a possible therapeutic target in these patients. In conclusion, this research highlights some interesting points of the complex relation between telomere length and outcome of patients treated for Chronic Myeloid Leukemia and Myelofibrosis. If confirmed, these findings will be a useful advance in understanding response to treatment in these populations.
APA, Harvard, Vancouver, ISO, and other styles
4

Dias, Dácio de Castro. "Hematologia e bioquímica sérica em muares." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/10/10136/tde-28072014-153256/.

Full text
Abstract:
Os objetivos deste trabalho foram determinar valores hematológicos e bioquímicos para muares de três faixas etárias e compará-los com os das raças formadoras. Para o desenvolvimento do trabalho foram utilizados 288 animais, machos ou fêmeas, sendo: 10 jumentos, 30 éguas e 260 muares. Os muares foram divididos em três grupos: G1 (animais entre dois meses e um ano de idade), G2 (animais entre um e três anos de idade) e G3 (animais acima de três anos de idade). Foram realizadas as seguintes avaliações laboratoriais: hemograma, contagem de plaquetas, fibrinogênio, glicemia, ureia, creatinina, creatinoquinase, aspartato aminotransferase, gama glutamiltransferase, fosfatase alcalina, lactato desidrogenase, bilirrubinas, proteína total, albumina, triglicérides, colesterol, lactato, sódio, cloro, potássio, cálcio, fósforo, magnésio e ferro. Além do estabelecimento dos valores de referência do hemograma e bioquímica sérica para muares de três faixas etárias, conclui-se também que: hematologicamente os muares estão mais próximos dos asininos que dos equinos; há diferença significativa nos valores bioquímicos e hematológicos entre as faixas etárias; há influência sexual nos valores hematológicos e bioquímicos de maures, mas é clinicamente menos significativa do que a influência etária; o hemoparasita Theileria equi pode ser encontrado no esfregaço sanguíneo de um número significativo de muares, mesmo que estes não apresentem sintomatologia clínica.
The purpose of this study was to determine hematological and biochemical values of three age groups of mules and to compare them with the forming races. For the development of this study, it was used 288 animals, males or females, as follows: 10 donkeys, 30 mares and 260 mules. The mules were divided into three groups: G1 (animals between two months and one year old), G2 (animals between one and three years old) and G3 (animals above three years old). The following laboratory evaluations were performed: blood count, platelet count, fibrinogen, glucose, urea, creatinine, creatine kinase, aspartate aminotransferase, gamma glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, bilirubin, total protein, albumin, triglycerides, cholesterol, lactate, sodium, chlorine, potassium, calcium, phosphorus, magnesium and iron. In addition to the establishment of reference values for blood count and serum biochemistry for mules of three age groups, it is also concluded that: hematologically, the mules are closer to donkeys than the horses; there is a significant difference in biochemical and haematological values between age groups; there is a sexual influence in the mules haematological and biochemical values, but it is clinically less significant than the age influence; the hemoparasite Theileria equi can be found in the blood smear in a significant number of mules, even if they do not show clinical symptoms.
APA, Harvard, Vancouver, ISO, and other styles
5

Cruz, Nathan da Rocha Neves [UNESP]. "Influência da anemia ferropriva no eletroforetrograma de hemoglobina de leitões." Universidade Estadual Paulista (UNESP), 2016. http://hdl.handle.net/11449/138874.

Full text
Abstract:
Submitted by Nathan da Rocha Neves Cruz (nathan_cruz@hotmail.com) on 2016-05-23T20:27:08Z No. of bitstreams: 1 CRUZ, N R N Dissertação FCAV 2016.pdf: 1407515 bytes, checksum: fedc8b43e90de16bd74b61d1621c28ad (MD5)
Approved for entry into archive by Juliano Benedito Ferreira (julianoferreira@reitoria.unesp.br) on 2016-05-25T18:00:38Z (GMT) No. of bitstreams: 1 cruz_nrn_me_jabo.pdf: 1407515 bytes, checksum: fedc8b43e90de16bd74b61d1621c28ad (MD5)
Made available in DSpace on 2016-05-25T18:00:38Z (GMT). No. of bitstreams: 1 cruz_nrn_me_jabo.pdf: 1407515 bytes, checksum: fedc8b43e90de16bd74b61d1621c28ad (MD5) Previous issue date: 2016-02-29
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
A hemoglobina é uma proteína globular composta por fração protéica (cadeias de globina), fração heme onde ocorre a ligação do íon bivalente de ferro, sendo que, as globinas combinadas ajudam a tipificar as hemoglobina em Hb Adulta (Hb A), Fetal (Hb F) e Adulta 2 (Hb A2). Na deficiência de ferro, que pode culminar anemia por disfunção eritropoiética, prevalente em leitões e seres humanos, a hemoglobina pode ter alterações estruturais denominadas hemoglobinopatias. O estudo determinou a influência do ferro nos tipos de hemoglobina de leitões neonatos. Perante os resultados se verificou que hemoglobina do leitão tem corrida semelhante à humana, e nos animais que apresentaram anemia ferropriva não houve aparecimento do traçado Hb A2, que pode estar diminuída em casos de deficiência de ferro em seres humanos.
Hemoglobin is a globular protein consisting of the protein fraction (globin chains), heme fraction which is the binding of the bivalent iron ion, and the combined globin help classify the hemoglobin in Hb Adult (Hb A), Fetal (Hb F) and Adult 2 (Hb A2). The iron deficiency can predispose anemia by erythropoietic dysfunction, prevalent in pigs and humans and the hemoglobin may have structural changes denominated hemoglobinopathies. The study determined the influence of iron to the types of hemoglobin neonate pigs. On the results was found that the pig hemoglobin is similar to human in electrophoresis. The piglets showed deficiency anemia there was appearance of line Hb A2, which may be diminished in cases of iron deficiency in humans.
CNPq: 158890/2015-9
CNPq: 130399/2014-0
CAPES: 23028003201-2014-41
APA, Harvard, Vancouver, ISO, and other styles
6

Cornacini, Fernando Henrique. "Interferência da variação sazonal de fatores ambientais no perfil hematológico e bioquímico metabólico de 'Chelonoidis carbonarius' /." São José do Rio Preto, 2020. http://hdl.handle.net/11449/192759.

Full text
Abstract:
Orientador: Claudia Regina Bonini-Domingos
Resumo: O “jabuti-piranga” (Chelonoidis carbonarius) é um jabuti brasileiro, amplamente distribuído entre os estados do Nordeste, ocorrendo em áreas de Cerrado e campo aberto, mas também presente em recintos de zoológicos e aquários, distribuídos por todo o território nacional. São animais ectotérmicos, cujo metabolismo e fisiologia são influenciados por condições ambientais (como temperatura, umidade relativa da atmosfera e luminosidade) em magnitudes superiores aos dos animais endotérmicos, como aves e mamíferos, por exemplo. O atual trabalho tem por objetivo avaliar como esses fatores ambientais influenciam no perfil hematológico e bioquímico de “jabuti-pirangas” em cativeiro durante o período de um ano. Foi observado que machos e fêmeas diferiram no perfil hematológico, em que os primeiros apresentaram maiores valores para hematócrito, hemoglobina e eritrócito; enquanto que no perfil bioquímico, machos obtiveram maiores valores para glicose e as fêmeas para colesterol e triglicérides. Entre os meses do ano, foi possível observar menores valores para concentração de hemoglobina circulante e correspondentes índices hematimétricos nos meses de outubro e dezembro; enquanto que a concentração de colesterol e triglicérides teve aumento significativo em dezembro e junho, para machos e apenas em dezembro, para as fêmeas. Foi possível concluir que: a variação sazonal dos fatores ambientais influencia diretamente nos parâmetros hematológicos, reduzindo a concentração de hemoglobinas circul... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: The “red-footed tortoise” (Chelonoidis carbonarius) is a Brazilian tortoise, widely distributed among the states of the Northeast, occurring in areas of Cerrado and open fields, but also present in enclosures of zoos and aquariums, distributed throughout the national territory. They are ectotermal animals, whose metabolism and physiology are more influenced by environmental conditions (such as temperature, relative humidity and luminosity) than they are in endothermic animals, such as birds and mammals, for example. The aim of the current study is to evaluate how these environmental factors influence the hematological and biochemical profile of “redfooted tortoises” in captivity during the period of one year. It has been observed that males and females differed in the hematological profile, in which the former had higher values for hematocrit, hemoglobin and erythrocyte; whereas in the biochemical profile, males obtained higher values for glucose and females for cholesterol and triglycerides. Between the months of the year, it was possible to observe lower values for circulating hemoglobin concentration and corresponding hematimetric indices in the months of October and December; while the concentration of cholesterol and triglycerides increased significantly in December and June, in males and only in December, in females. It was possible to conclude the following: the seasonal variation of the environmental factors directly influences the hematological parameters, reducing t... (Complete abstract click electronic access below)
Mestre
APA, Harvard, Vancouver, ISO, and other styles
7

Bistué, Rovira Àngel. "Potencial ús de la curcumina en el tractament de la Leucèmia Limfocítica Crònica." Doctoral thesis, Universitat Autònoma de Barcelona, 2020. http://hdl.handle.net/10803/671047.

Full text
Abstract:
La curcumina és un compost fenòlic present en el rizoma de la Curcuma longa, que ha estat extensament estudiat en diversos models de càncer, per les seves propietats proapoptòtiques, antiinflamatòries i quimiosensibilitzadores, entre d’altres. Els seus efectes com a inhibidor enzimàtic en múltiples vies metabòliques relacionades amb la progressió del càncer la fan un compost molt selectiu, amb activitat antineoplàsica alhora que presenta una molt baixa toxicitat. La Leucèmia Limfocítica Crònica (LLC) és una malaltia hematològica d’elevada incidència en països occidentals, originada per una expansió patològica de les cèl·lules B, a causa d’unes taxes d’apoptosi reduïdes. Malgrat que les taxes de proliferació d’aquestes cèl·lules solen ser més baixes que en altres neoplàsies, són molt difícils d’erradicar completament, i els pacients solen recaure amb el temps. La progressió de la malaltia cap a fases més avançades, que requereixen tractaments més complexos i freqüents, acaba afectant la qualitat de vida dels pacients i limitant-ne l’esperança de vida, de manera que resulta d’elevat interès trobar millores en les teràpies que permetin, per una banda, reduir les dosis i els efectes adversos, i per una altra, millorar el tractament i retardar la progressió. En aquesta Tesi Doctoral s’ha estudiat l’efecte de la curcumina sobre models cel·lulars derivats de LLC, així com en cultius primaris obtinguts a partir de sang perifèrica de pacients amb LLC, a fi de valorar el potencial per induir apoptosi sobre les cèl·lules d’aquesta leucèmia. Les primeres anàlisis van consistir en mesurar sobre tres models cel·lulars de LLC (I83, Mec1 i EHEB) l’efecte sinèrgic de la curcumina en combinació amb diversos fàrmacs proapoptòtics (camptotecina, colquicina), antineoplàsics (etopòsid i citarabina) i utilitzats en el tractament de la LLC (fludarabina). Es va mesurar per citometria de flux l’efecte citotòxic produït en funció de la pèrdua de la integritat de la membrana cel·lular i el bloqueig de la proliferació, així com els efectes sobre el cicle cel·lular. A més, es van realitzar citocentrifugacions de les mostres i es van analitzar per microscòpia òptica per avaluar els efectes produïts sobre la citomorfologia. L’efecte sinèrgic de la curcumina també es va valorar sobre cultius primaris derivats de sang perifèrica de pacients amb LLC. En aquest cas, la curcumina va ser combinada amb diversos fàrmacs utilitzats en el tractament de la LLC: fludarabina, ibrutinib i rituximab. Mitjançant la citometria de flux, es va identificar la població leucèmica, així com les subpoblacions amb característiques de cèl·lula mare, més primitives i refractàries (mitjançant els nivells d’activitat de la fosfatasa alcalina) i es va mesurar l’efecte dels diferents tractaments sobre les cèl·lules. Finalment, s’ha avaluat l’efecte modulador de la curcumina sobre diversos mecanismes implicats en l’apoptosi de les cèl·lules i la refractarietat als tractaments. Així, s’han avaluat els efectes sobre la producció d’espècies reactives de l’oxigen (ROS), sobre l’extrusió de fàrmacs i sobre l’activitat caspasa. La curcumina va mostrar un efecte sinèrgic variable en combinació amb els diversos fàrmacs testats, tant en models cel·lulars com en cultius primaris, i va produir un augment de la citotoxicitat, un bloqueig del cicle cel·lular i una reducció dels percentatges de cèl·lules amb característiques de cèl·lula mare leucèmica. A més, la curcumina va mostrar activitat en certs casos modulant la producció de ROS, la capacitat d’extrusió de fàrmacs i generant l’activació de les caspases. Els resultats obtinguts confirmen el potencial proapoptòtic i adjuvant de la curcumina i justifiquen la realització de nous estudis dirigits a una potencial implementació de la curcumina en els tractaments.
La curcumina es un compuesto fenólico presente en el rizoma de la Curcuma longa, que ha sido estudiado en varios modelos de cáncer, por sus propiedades proapoptóticas, antiinflamatorias y quimiosensibilizadoras, entre otras. Sus efectos como inhibidor enzimático en múltiples vías metabólicas relacionadas con la progresión del cáncer la hacen un compuesto muy selectivo, con actividad antineoplásica a la vez que presenta una muy baja toxicidad. La Leucemia Linfocítica Crónica (LLC) es una enfermedad hematológica de elevada incidencia en países occidentales, originada por una expansión patológica de las células B, debido a unas tasas de apoptosis reducidas. A pesar de que la proliferación de estas células suele ser menor que en otras neoplasias, son muy difíciles de erradicar completamente, y los pacientes suelen recaer con el tiempo. La progresión de la enfermedad hacia fases más avanzadas, que requieren tratamientos más complejos y frecuentes, afecta la calidad de vida de los pacientes y limita su esperanza de vida, por lo que resulta de elevado interés encontrar mejoras en las terapias que permitan, por una parte, reducir las dosis y los efectos adversos, y por otra, mejorar el tratamiento y retrasar la progresión. En esta Tesis Doctoral se ha estudiado el efecto de la curcumina sobre modelos celulares de LLC, y en cultivos primarios obtenidos a partir de sangre periférica de pacientes con LLC, a fin de valorar el potencial para inducir apoptosis sobre las células de esta leucemia. Los primeros análisis consistieron en medir sobre tres modelos celulares de LLC (I83, MEC1 y EHEB) el efecto sinérgico de la curcumina en combinación con varios fármacos proapoptóticos (camptotecina, colchicina), antineoplásicos (etopósido y citarabina) y utilizados en el tratamiento de la LLC (fludarabina). Se midió por citometría de flujo del efecto citotóxico producido en función de la pérdida de la integridad de la membrana celular y el bloqueo de la proliferación, así como los efectos sobre el ciclo celular. Además, se realizaron citocentrifugaciones de las muestras y se analizaron por microscopía óptica para evaluar los efectos producidos sobre la citomorfologia. El efecto sinérgico de la curcumina también se valoró sobre cultivos primarios derivados de sangre periférica de pacientes con LLC. En este caso, la curcumina fue combinada con varios fármacos utilizados en el tratamiento de la LLC: fludarabina, ibrutinib y rituximab. Mediante citometría de flujo, se identificó la población leucémica, y las subpoblaciones con características de célula madre, más primitivas y refractarias (mediante los niveles de actividad de la fosfatasa alcalina) y se midió el efecto de los diferentes tratamientos sobre las células. Finalmente, se evaluó el efecto modulador de la curcumina sobre varios mecanismos implicados en la apoptosis de las células y la refractariedad a los tratamientos. Así, se han evaluado los efectos sobre la producción de especies reactivas del oxígeno (ROS), sobre la extrusión de fármacos y sobre la actividad caspasa. La curcumina mostró un efecto sinérgico variable en combinación con los fármacos testados, tanto en modelos celulares como en cultivos primarios, y produjo un aumento de la citotoxicidad, un bloqueo del ciclo celular y una reducción de los porcentajes de células con características de célula madre leucémica. Además, la curcumina mostró actividad en ciertos casos modulando la producción de ROS, la capacidad de extrusión de fármacos y generando la activación de las caspasas. Los resultados obtenidos confirman el potencial proapoptótico y adyuvante de la curcumina y justifican la realización de nuevos estudios dirigidos a una potencial implementación de la curcumina en los tratamientos.
Curcumin is a phenolic compound present in the rhizome of Curcuma longa, which has been extensively studied in various cancer models, for its proapoptotic, anti-inflammatory and chemosensitizing properties, among others. Its effects as an enzyme inhibitor in multiple metabolic pathways related to cancer progression make it a very selective compound, with antineoplastic activity while presenting low toxicity. Chronic Lymphocytic Leukemia (CLL) is a high-incidence hematologic disease in Western countries, caused by a pathological expansion of B cells, due to reduced rates of apoptosis. Although the proliferation rates of these cells are usually lower than in other neoplasms, they are difficult to eradicate completely, and patients often relapse over time. The progression of the disease to more advanced stages, which require more complex and frequent treatments, results in a reduction of the quality of life of patients and limiting their life expectancy, so it is of great interest to improve therapies, which would allow, on the one hand, to reduce the doses and the adverse effects, and on the other hand, to improve the treatment and to delay the progression. This Doctoral Thesis has studied the effect of curcumin on cell models derived from CLL, as well as in primary cultures obtained from peripheral blood of patients with CLL, in order to assess the potential to induce apoptosis on the cells of this leukemia. The first analysis consisted on measuring on three cellular models of CLL (I83, Mec1 and EHEB) the synergistic effect of curcumin in combination with various proapoptotic drugs (camptothecin, colchicine), antineoplastics (etoposide and cytarabine) and used in treatment of CLL (fludarabine). Flow cytometry was used to measure the cytotoxic effect produced depending on the loss of cell membrane integrity and proliferation blockade, as well as effects on the cell cycle. In addition, cytocentrifugations of the samples were performed and analyzed by optical microscopy to evaluate the effects produced on cytomorphology. The synergistic effect of curcumin was also assessed on primary cultures derived from peripheral blood from patients with CLL. In this case, curcumin was combined with several drugs used in the treatment of CLL: fludarabine, ibrutinib, and rituximab. Leukemic population was identified by flow cytometry, as well as the subpopulations with more primitive and refractory stem cell characteristics (detected using alkaline phosphatase activity levels) and the effect of the different treatments on cells. Finally, the modulatory effect of curcumin on various mechanisms involved in cell apoptosis and refractoryness to treatments has been evaluated. Thus, the effects on reactive oxygen species (ROS) production, drug extrusion, and caspase activity have been evaluated. Curcumin showed a variable synergistic effect in combination with tested drugs, both in cell models and in primary cell cultures, and produced an increase in cytotoxicity, a blockage of the cell cycle and a reduction of cells with leukemic stem cell characteristics. In addition, curcumin showed activity in certain cases by modulating ROS production, drug extrusion capacity, and generating caspase activation. The results obtained confirm the proapoptotic and adjuvant potential of curcumin and justify the performance of new studies aimed at a potential implementation of curcumin in treatments.
APA, Harvard, Vancouver, ISO, and other styles
8

Gomes, Monteiro Lopes Baptista Maria João. "Molecular mechanisms of apoptosis induced by dexamethasone in chronic lymphocytic leukemia." Doctoral thesis, Universitat de Barcelona, 2012. http://hdl.handle.net/10803/92558.

Full text
Abstract:
Glucocorticoids are frequently included in the chemotherapy regimens administered to patients with CLL because they are potent immunosuppressant agents and because they are able to induce apoptosis in CLL cells. Although used from a long time, the molecular mechanisms by which glucocorticoids induce cell death in CLL cells are largely unknown. Interestingly, CLL cells from prognostic groups defined by the mutational load of the IGHV genes and the expression of ZAP70 seem to have different responses to glucocorticoids. The hypothesis in this thesis is that there are genes or proteins that determine the different response to glucocorticoids among the specific prognostic groups of patients with CLL. Sensitivity to dexamethasone was analyzed ex vivo in 50 CLL and compared according to IGHV mutational status and/or ZAP70 expression. The response was further compared by gene expression profiling (GEP) of selected cases. Expression of genes of interest was validated by quantitative reverse transcriptase PCR. Response to dexamethasone is higher in cases with unmutated IGHV/high ZAP70 expression and the levels of induction of the pro-apoptotic BIM gen correlate with the degree of cell death. The different levels of apoptosis induced by dexamethasone observed in the CLL groups defined by ZAP70 expression translate into different profiles of gene expression. These differences are mainly quantitative; cases with high ZAP70 expression show higher levels of gene induction/repression than cases with low ZAP70 expression. Specific analysis of genes of interest performed in a large series disclosed that baseline mRNA and protein expression levels of FKBP5, the co-chaperone of the glucocorticoid receptor, correlate with the extent of CLL cells apoptosis induced by the treatment with dexamethasone. Baseline FKBP5 levels are higher in samples from patients with high ZAP70 expression. GILZ is differentially induced by dexamethasone in ZAP70 expression groups of CLL, being higher in cases with high ZAP70 expression. Induction of GILZ correlates with induction of BIM and levels of apoptosis. Unmutated IGHV/high ZAP70 CLL cells exhibit better response to dexamethasone treatment, which is accompanied by a differential expression of genes involved in the glucocorticoid-receptor pathway and by an increased induction of genes related to apoptosis.
Los glucocorticoides son frecuentemente incluidos en la quimioterapia administrada a pacientes con leucemia linfática crónica (LLC), pues son potentes inmunosupresores e inducen la apoptosis de las células de LLC. Los mecanismos moleculares por los cuales los glucocorticoides inducen la apoptosis de las células de LLC son en gran parte desconocidos. Las células LLC de grupos pronósticos definidos por el estado mutacional de los genes IGHV y por la expresión de ZAP70 parecen tener diferentes respuestas a los glucocorticoides. La hipótesis de esta tesis es que hay genes o proteínas expresados de forma diferente en los grupos pronósticos de pacientes con LLC que determinan los diferentes niveles de apoptosis inducidos por los glucocorticoides. La sensibilidad al glucocorticoide dexametasona, se determino ex vivo en 50 muestras de pacientes con LLC y se comparo en función del estado mutacional de los genes IGHV y/o de la expresión de ZAP70. También se compararan los perfiles de expresión génica (GEP) de casos seleccionados. Los niveles de expresión de los genes de interés se validaran por QRT-PCR. La respuesta a la dexametasona es superior en los casos de LLC con genes IGHV no mutados/alta expresión de ZAP70. Los niveles de inducción del gen proapoptótico BIM se correlacionan con el grado de muerte celular. Los diferentes niveles de apoptosis inducida por dexametasona en los grupos de LLC definidos por la expresión de ZAP70 se traducen diferentes GEP. Las diferencias entre los GEP de cada grupo fueran principalmente cuantitativas, los casos con alta expresión de ZAP70 muestran niveles más altos de inducción/represión génica que los casos con baja expresión. Se observo que los niveles basales de ARNm y proteína de FKBP5, una cochaperona del receptor de los glucocorticoides, se correlacionan con el grado de apoptosis inducida por la dexametasona y que los niveles de FKBP5 son más elevados en los casos con alta expresión de ZAP70. GILZ induce diferencialmente por la dexametasona, observándose mayores inducciones en los casos con alta expresión de ZAP70. La inducción de GILZ se correlaciona con la inducción de BIM y con la magnitud de la apoptosis.
APA, Harvard, Vancouver, ISO, and other styles
9

Medeiros, Fernanda Peres. "Variação da ecogenicidade difusa em parênquima hepático homogêneo relacionada aos achados bioquímicos e hematológicos em cães /." Jaboticabal :, 2009. http://hdl.handle.net/11449/89047.

Full text
Abstract:
Orientador: Julio Carlos Canola
Banca: Áureo Evangelista Santana
Banca: Georgea Bignardi Jarretta
Resumo: No presente estudo foi analisado o parênquima hepático com características homogêneas e ecogenicidade difusa reduzida (G1), aumentada (G2) e normal (G3), em relação ao perfil dos animais, dimensão do fígado e achado bioquímico e hematológico. Amostras de sangue obtidas por punção venosa da jugular ou da cefálica do antebraço foram encaminhadas para realização de hemograma e dosagem sérica de ALT, FA, proteínas totais, albumina, globulina, uréia e creatinina. Dos 30 cães que compuseram o G1, 30 (100%) apresentaram evidência das paredes portais e da vesícula biliar, 23 (76,67%) fígado com dimensão preservada e bordos em ângulos agudos, 15 (50%) faixa etária entre 1 e 6 anos de idade e 8 (26,67%) eram da raça lhasa apso. Não houve predisposição quanto ao sexo, assim como não foram identificadas alterações significativas nos exames bioquímicos e hematológicos dos cães do G1. Quanto aos diagnósticos clínicos atribuídos para estes cães, houve maior prevalência de gastrinterite (43,33%). Dos 30 cães do G2, 27 animais (90%) apresentaram hepatomegalia e arredondamento dos bordos hepáticos, 18 (60%) tinham idade superior a 9 anos, 16 (53,33%) eram fêmeas e 9 (30%) eram da raça poodle. Houve elevação da atividade sérica de FA e elevação de ALT, redução nos níveis de proteínas séricas totais, albumina, globulinas, eritrócitos e volume globular, além de leucocitose por neutrofilia, com desvio à esquerda, eosinopenia, linfopenia e monocitose nos cães do G2. Neste grupo houve prevalência de doenças metabólicas (54%), como diabetes mellitus e hiperadrenocorticismo, além das hepatopatias crônicas (17%), atribuídas ao uso contínuo e prolongado de corticóide e drogas anticonvulsivantes. Dos 30 cães do grupo controle (G3), 22 (73,33%) apresentaram... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: The present study evaluated the liver with homogeneous parenchyma in dogs, with diffuse reduced echogenicity (G1), increased echogenicity (G2) and normal echogenicity (G3) by ultrasound examination associating the findings on animal profile, liver size and hematology and biochemistry results. Blood samples obtained by cephalic or jugular venipunture were submitted for hemogram and ALT, ALP, total proteins, albumin, globulin, urea and creatinine analysis. Among the 30 dogs in G1, 30 (100%) presented portal venous and gall bladder wall clarity, 23 (76.67%) presented normal liver size and edges, 15 (50%) were from 1 to 6 years old and 8 (26.67%) belonged to the lhasa apso breed. No predispositions were found according to gender, as well as no significant alterations in biochemical and hematological exams were observed in G1. The most prevalent disease found in this group was gastroenteritis (43.33%). Among the 30 dogs in G2, 27 (90%) presented hepatomegaly and rounded hepatic edges, 18 (60%) were over 9 years old, 16 (53.33%) were female and 9 (30%) belonged to the poodle breed. The laboratorial findings related to this group were increased ALT and ALP serum activity, decreased levels of total protein, albumin, globulin, erythrocytes and hematocrit, as well as leukocytosis with neutrophilia and a left shift, eosinopenia, lymphopenia and monocytosis. The most prevalent diseases found in this group were metabolic disorders (54%), such as diabetes mellitus and hyperadrenocorticism, and chronic hepatopathies (17%) due to prolonged and continuous use of corticoid and anticonvulsive drugs. Among the 30 dogs in the control group (G3), normal liver size and edges were presented in 22 (73.33%). In this group, no alterations were seen in laboratorial exams.
Mestre
APA, Harvard, Vancouver, ISO, and other styles
10

Mendonça, Adriane Jorge. "Avaliação hematológica, bioquímica e hemostática de bezerros Brahman provenientes de produção in vitro (PIV) e bezerros Brahman de produção in vivo /." Botucatu, 2007. http://hdl.handle.net/11449/101311.

Full text
Abstract:
Orientador: Regina kiomi Takahira
Banca: Raimundo Souza Lopes
Banca: Alexandre Secorun Borges
Banca: Graziela Barioni
Banca: Mara Regina Stipp Balarin
Resumo: Avaliou-se alterações na hematologia, bioquímica e hemostasia de 112 bezerros Brahman produzidos in vitro (PIV) comparados a 20 bezerros Brahman produzidos in vivo, bem como avaliou-se a influência dos fatores etários e sexuais sobre os mesmos exames laboratoriais nos bezerros PIV em segundo estudo. Para tanto, os 112 bezerros PIV foram divididos em 4 grupos: 0-15 dias, 16-40 dias, 60-80 dias e 81-100 dias de idade com subdivisões para sexo em cada grupo. Todos foram submetidos aos exames de hemograma, às avaliações bioquímicas da uréia, creatinina, das proteínas totais séricas (PTS), albumina e globulina e da atividade sérica das enzimas aspartato amino transferase (AST) e creatina cinase (CK). A hemostasia foi avaliada pela determinação do tempo de protrombina (TP), tempo de tromboplastina parcial ativada (TTPA) e concentração do fibrinogênio. Analisando os resultados, concluiu-se que houve influência da produção in vitro nos valores bioquímicos do soro de bezerros Brahman manifestados por aumento das globulinas e diminuição da albumina em animais PIV; o fator etário influenciou na variação dos parâmetros analisados, refletidos por diminuição de neutrófilos segmentados, monócitos, uréia, CK, PTS, globulinas e fibrinogênio, e por aumento dos linfócitos e da creatinina com o avanço da idade. Machos tem valores médios de linfócitos (grupos de 0-15 e 60-80 dias de idade) e leucócitos totais (grupo de 60-80 dias) superiores às fêmeas. Fêmeas tem valores médios de monócitos (grupos de 16-40 e 60-80 dias) e de CK (grupo de 16-40 dias de idade) superiores aos machos
Abstract: Changes on hematology, biochemistry and hemostasis were evaluated in 112 Brahman's calves derived from in vitro-produced embryos (IVP) compared with 20 Brahman's calves derived from in vivo production. Age and sexual influences were evaluated on 112 IVP Brahman's calves divided in four groups: 0-15, 16-40, 60-80 and 81-100 days of age; each group were further subdivided according to their gender. All calves were submitted to the following laboratory tests: hemogram, urea, creatinine, total serum proteins (TSP), albumin and globulin levels and the serum activities of aspartate aminotransferase (AST) and creatine kinase (CK). The hemostasis was evaluated by the prothrombim time (PT), activated partial thromboplastin time (aPTT) and fibrinogen concentration. According to the results, it was concluded that albumin and globulin were influenced by the IVP, characterized by an increase in globulin and a decrease in albumin in IVP animals. Age have influenced the variation on the parameters analyzed, characterized by a decrease in the segmented neutrophils, monocytes, urea, CK, TSP, albumin and fibrinogen concentrations, and a creatinine increase with the age advance. Males has higher lymphocytes (groups of 0-15 and 60-80 days of age) and leukocytes (group of 60-80 days of age) values than females. Females has higher monocytes (groups 16-40 and 60-80 days of age) and CK (group of 16-40 days of age) values than males
Doutor
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Hematology"

1

Wintrobe, Maxwell Myer. Clinical hematology. [s.l: s.n.], 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1901-, Wintrobe Maxwell Myer, and Lee G. Richard, eds. Wintrobe's clinical hematology. Baltimore: Williams & Wilkins, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1901-, Wintrobe Maxwell Myer, and Greer John P. MD, eds. Wintrobe's clinical hematology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1901-, Wintrobe Maxwell Myer, and Greer John P, eds. Wintrobe's clinical hematology. Philadelphia: Lippincott Williams & Wilkins, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1923-, Beck William Samson, ed. Hematology. 4th ed. Cambridge, Mass: MIT Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

S, Beck William, ed. Hematology. 4th ed. Cambridge, Mass: MIT Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ernest, Beutler, and Williams William J, eds. Williams hematology. 5th ed. New York: McGraw-Hill, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Beck, William S., ed. Hematology. Cambridge: MIT Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

McKenzie, Shirlyn B. Textbook of hematology. 2nd ed. Baltimore: Williams & Wilkins, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1928-, Beutler Ernest, and Williams William J. 1926-, eds. Williams hematology. 6th ed. New York: McGraw-Hill, Health Professions Division, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hematology"

1

Lee, Melinda A., and John R. Walsh. "Hematology." In Geriatric Medicine, 330–46. New York, NY: Springer New York, 1990. http://dx.doi.org/10.1007/978-1-4757-2093-8_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Allen, Brandon, Latha Ganti, and Bobby Desai. "Hematology." In Quick Hits in Emergency Medicine, 87–88. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7037-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stewart, Jill. "Hematology." In Oklahoma Notes, 193–227. New York, NY: Springer New York, 1996. http://dx.doi.org/10.1007/978-1-4612-4006-8_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hirsch, Jeffrey G. "Hematology." In Oklahoma Notes, 237–60. New York, NY: Springer New York, 1996. http://dx.doi.org/10.1007/978-1-4612-4010-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hui, David. "Hematology." In Approach to Internal Medicine, 143–84. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-6505-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sherazi, Mubashar Hussain. "Hematology." In The Objective Structured Clinical Examination Review, 411–27. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-95444-8_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Faye, Bernard, and Mohammed Bengoumi. "Hematology." In Camel Clinical Biochemistry and Hematology, 13–45. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-95562-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

MacNeill, Amy L. "Hematology." In Clinical Pathology and Laboratory Techniques for Veterinary Technicians, 19–74. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119421351.ch2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jarolim, Dala R. "Hematology." In Oklahoma Notes, 174–200. New York, NY: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4684-0458-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hirsch, Jeffrey G. "Hematology." In Oklahoma Notes, 214–27. New York, NY: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4684-0476-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hematology"

1

Astuti, Dewi, Eva Ayu Maharani, and Fitri Zakiyah. "The Comparison of Routine Hematology Test Between Veins and Capillary Blood: Studies on Hematology Analyzer." In Proceedings of the 5th International Conference on Health Sciences (ICHS 2018). Paris, France: Atlantis Press, 2019. http://dx.doi.org/10.2991/ichs-18.2019.10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nitsch, Thorsten, Julia Lanznaster, and Thomas Südhoff. "Ultrasound guided biopsy in hematology and oncology." In 46. Dreiländertreffen der DEGUM in Zusammenarbeit mit ÖGUM & SGUM. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1772355.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sullivan, Stephanie M., Brian G. Jamieson, and Bradley E. Layton. "A Micro-Fabricated Electrical Impedance Based Hematology Analyzer." In ASME 2005 International Mechanical Engineering Congress and Exposition. ASMEDC, 2005. http://dx.doi.org/10.1115/imece2005-79446.

Full text
Abstract:
Our work proposes a device to monitor and measure three key hematology parameters: red blood cell count (RBC), mean red blood cell volume (MCV), and red blood cell distribution width (RDW). This device will be a microfabricated microchannel unit. Cellular detection will be performed using an impedance device through a series of filter beds with channel dimensions of approximately 2–7 μm wide × 5 μm high × 5–15 μm long.
APA, Harvard, Vancouver, ISO, and other styles
4

Bevilacqua, Vitoantonio, Domenico Buongiorno, Pierluigi Carlucci, Ferdinando Giglio, Giacomo Tattoli, Attilio Guarini, Nicola Sgherza, et al. "A supervised CAD to support telemedicine in hematology." In 2015 International Joint Conference on Neural Networks (IJCNN). IEEE, 2015. http://dx.doi.org/10.1109/ijcnn.2015.7280464.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hayden, Oliver. "Hematology analysis with holographic imaging cytometry (Conference Presentation)." In Quantitative Phase Imaging V, edited by Gabriel Popescu and YongKeun Park. SPIE, 2019. http://dx.doi.org/10.1117/12.2513270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pizzi, Nicolino J., Sandhya Kapoor, and Jon M. Gerrard. "Hematology Expert System (HES) For Tonsillectomy/Adenoidectomy Patients." In SPIE 1989 Technical Symposium on Aerospace Sensing, edited by Mohan M. Trivedi. SPIE, 1989. http://dx.doi.org/10.1117/12.969339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Colella, G. M., D. H. Tycko, and W. Groner. "Technicon H*1 Hematology System: Optical Design Considerations." In 1988 Los Angeles Symposium--O-E/LASE '88, edited by Kazuhiko Atsumi and Stephen N. Joffe. SPIE, 1988. http://dx.doi.org/10.1117/12.945330.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Young, Carole, and Jai Navlakha. "Expert Assistant For A Clinical Hematology Blood Cell Analyzer." In SPIE 1989 Technical Symposium on Aerospace Sensing, edited by Mohan M. Trivedi. SPIE, 1989. http://dx.doi.org/10.1117/12.969340.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Layton, Bradley E., Brian G. Jamieson, and Stephanie M. Sullivan. "A Micro-Fabricated Electrical-Impedance-Based In-Flight Hematology Analyzer." In ASME 3rd International Conference on Microchannels and Minichannels. ASMEDC, 2005. http://dx.doi.org/10.1115/icmm2005-75219.

Full text
Abstract:
We present a proposed method to obtain three hematology parameters: red blood cell count, mean red blood cell volume and red blood cell distribution width on a microfabricated microchannel device. Detection will be conducted with an impedance device, in a series of three or more filter beds with channel dimensions on the order of 2–7 μm wide × 5 μm high × 5–15 μm long, and a total device volume on the order of 1 μl.
APA, Harvard, Vancouver, ISO, and other styles
10

Lou, Rachel, and Thanh Le. "A Linear, Pixel-specific Color Normalization Algorithm for Hematology Imaging." In 8th International Conference on Bioimaging. SCITEPRESS - Science and Technology Publications, 2021. http://dx.doi.org/10.5220/0010344300002865.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hematology"

1

Lin, Zhijuan, Xing Chen, Long Liu, Zhifeng Li, and Bing Xu. Chemo-Free Treatments in Relapsed and/or Refractory Follicular Lymphoma: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0111.

Full text
Abstract:
Review question / Objective: FL is the most common indolent B cell lymphoma worldwide and patients with FL always have long term survival. However, advanced FL remains incurable and there is no universal agreement on optimal regimen to manage relapsed FL. Condition being studied: The efficacy of chemo-free regimens, including CD20 antibodies and targeted agents, in relapsed and/or refractory Follicular lymphoma. Information sources: We used the MEDLINE, Embase, and Cochrane Library databases to search the RCTs met our selection criteria. We also searched clinicalTrials.gov and the international clinical trial registry platform for completed and ongoing trials. In addition, we searched abstracts that published on American Society of Hematology (ASH), The European Hematology Association (EHA) or American Society of Clinical Oncology (ASCO) meetings.
APA, Harvard, Vancouver, ISO, and other styles
2

Vakhlova, I. V., and Yu N. Ibragimova. Electronic educational resource (EOR) "Hematology: Iron deficiency anemia in children". SIB-Expertise, February 2023. http://dx.doi.org/10.12731/er0673.21022023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Corinna Hazelrig, Corinna Hazelrig. Assessing snake health in the southeastern United States through pathogen surveillance and hematology. Experiment, April 2022. http://dx.doi.org/10.18258/26187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shen, Meixiao, Juan Wang, Meiqing Lei, and Zhiming Wang. The clinical characteristics and outcome of mucormycosis among patients with hematology diseases: a systematic and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2023. http://dx.doi.org/10.37766/inplasy2023.7.0069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Press, O. W. Improved radioimmunotherapy of hematologic malignancies. Office of Scientific and Technical Information (OSTI), March 1992. http://dx.doi.org/10.2172/5376292.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Press, O. W. Improved radioimmunotherapy of hematologic malignancies. [Final report]. Office of Scientific and Technical Information (OSTI), March 1992. http://dx.doi.org/10.2172/10141667.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Press, O. W. Improved radioimmunotherapy of hematologic malignancies. Final technical report. Office of Scientific and Technical Information (OSTI), August 1996. http://dx.doi.org/10.2172/373849.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Press, O. W., and D. F. Barofsky. Improved radioimmunotherapy of hematologic malignancies. Progress report, 1988--1991. Office of Scientific and Technical Information (OSTI), December 1991. http://dx.doi.org/10.2172/10112383.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bunner, David L., Harold A. Neufeld, Lucas H. Brennecke, Yvette G. Campbell, and Richard E. Dinterman. Clinical and Hematologic Effects of T-2 Toxin in Rats. Fort Belvoir, VA: Defense Technical Information Center, August 1985. http://dx.doi.org/10.21236/ada158874.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Beidleman, Beth A., Janet E. Staab, Stephen R. Muza, and Michael N. Sawka. Predicted Hematologic and Plasma Volume Responses Following Rapid Ascent to Progressive Altitudes. Fort Belvoir, VA: Defense Technical Information Center, June 2014. http://dx.doi.org/10.21236/ada614246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography